Chemokine receptors: Attractive targets for drug discovery

Annals of the New York Academy of Sciences

Volumn 1051, Issue , 2005, Pages 647-657

  Godessart, Nuria ^a  

^a Almirall Research Center ^*  (Spain)

Author keywords

Autoimmune diseases; Chemokines; Chronic inflammation; Drug discovery; G protein coupled receptors; Leukocyte recruitment; Target validation

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; 1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 4 [3 [4 (3,4 DICHLOROBENZYL) 2 MORPHOLINYLMETHYL]UREIDOMETHYL]BENZAMIDE; ADALIMUMAB; AMD 070; AMG 714; APLAVIROC; ASELIZUMAB; BERTILIMUMAB; BETA1A INTERFERON; BIMOSIAMOSE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR6; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; CP 481715; CTCE 0214; DPC 168; EFALIZUMAB; ETANERCEPT; FINGOLIMOD; FOCAL ADHESION KINASE 2; G PROTEIN COUPLED RECEPTOR; GUANOSINE TRIPHOSPHATASE; INFLIXIMAB; INTEGRIN; L 888839; MARAVIROC; MLN 1202; MLN 3701; MLN 3897; MRA; NATALIZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; T 0906487; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ASTHMA; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD VESSEL INJURY; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONJUNCTIVITIS; DRUG RESEARCH; DRUG TARGETING; ECZEMA; GRAFT REJECTION; HAY FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE MIGRATION; MULTIPLE SCLEROSIS; NONHUMAN; PSORIASIS; TH1 CELL; TH2 CELL;

EID: 25444449772     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1361.109     Document Type: Conference Paper

References (49)

1. LUSTER, A.D. 1998. Chemokines-chemotactic cytokines that mediate inflammation. N. Engl. J. Med. 338: 436-445.
2. ZLOTNIK, A. & O. YOSHIE. 2000. Chemokines: a new classification system and their role in immunity. Immunity 12: 121-127.
3. GERARD, C. & B.J. ROLLINS. 2001. Chemokines and disease. Nat. Immunol. 2: 108-115.
4. GODESSART, N. & S.L. KUNKEL. 2001. Chemokine in autoimmune disease. Curr. Opin. Immunol. 13: 670-675.
5. MURPHY, P.M., et al. 2000. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52: 145-176.
6. ONUFFER, J. & R. HORUCK. 2002. Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Trends Pharm. Sci. 23: 459-467.
7. JOHNSON, Z. et al. 2004. Chemokine inhibition - why, when where, which and how? Biochem. Soc. Trans. 32: 366-377.
8. MOSER, B. et al. 2004. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25: 75-84.
9. BARDI, G. et al. 2001. The T cell chemokine receptor CCR7 is internalized on stimulation with ELC, but not with SLC. Eur. J. Immunol. 31: 3291-3297.
10. KOHOUT, T.A. et al. 2004. Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J. Biol Chem. 279: 23214-23222.
11. MARIANI, M. et al. 2004. Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells. Eur. J. Immunol. 34: 231-240.
12. TERRICABRAS, E., C. BENJAMIN & N. GODESSART. 2004. Drug discovery and chemokine receptor antagonists: eppur si muove! Autoimmunity Rev. 3: 550-556.
13. PETKOVIC, V. et al. 2004. Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. A human chemokine with a regulatory role. J. Biol. Chem. 279: 23357-23363.
14. OGILVIE, P. et al. 2003. Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood 102: 789-794.
15. OGILVIE, P. et al. 2004. Unusual chemokine receptor antagonism involving a mitogen-activated protein kinase pathway. J. Immunol. 172: 6715-6722
16. LOETSCHER, P. et al. 2001. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3. J. Biol. Chem. 276: 2986-2991.
17. XANTHOU, G. et al. 2003. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Eur. J. Immunol. 33: 2241-2250.
18. PETKOVIC, V. et al. 2004. I-TAC/CXCL11 is a natural antagonist for CCR5. J. Leukoc. Biol. 76: 701-708.
19. LASAGNI, L. et al. 2003. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J. Exp. Med. 197: 1537-1549.
20. FULKERSON, P.C. et al. 2004. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-gamma (Mig, CXCL9). Proc. Natl. Acad. Sci. USA 101: 1987-1992.
21. THOMAS, M.S. et al. 2004. Regulation of cockroach antigen-induced allergic airway hyperreactivity. J. Immunol. 173: 615-623.
22. MIYASAKA, M. & T. TANAKA. 2004. T lymphocyte trafficking across high endothelial venules: dogmas end enigmas. Nat. Rev. Immunol. 4: 360-370.
23. IMHOF, B.A. & M. AURRAND-LIONS. 2004. Adhesion mechanisms regulating the migration of monocytes. Nat. Rev. Immunol. 4: 432-444.
24. O'CONNOR, P.W. et al. 2004. Natalizumab Multiple Sclerosis Trial Group. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 62: 2038-2043.
25. SANDBORN, W. et al. 2004. A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn's disease (ENACT-2). Gastroenterology 127: 332-339.
26. LEBWOHL, M. et al. 2003. Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. 349: 2004-2013.
27. BRINKMANN, V. 2004. FTY720: Mechanism of action and potential benefit in organ transplantation. Yonsei Med. J. 45: 991-997.
28. ROVIEZZO, F. et al. 2004. Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate. Proc. Natl. Acad. Sci. USA 101: 11170-11175.
29. YOPP, A.C. et al. 2004. FTY720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J. Immunol. 173: 855-865.
30. BENOIT, S., A. TOKSOY, E.B. BROCKER, et al. 2004. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br. J. Dermatol. 150: 1009-1012
31. SCHWARZ, M.K. & T.N.C. WELLS. 2002. New therapies that modulate chemokine networks. Nat. Rev. Drug Discov. 1: 347-358.
32. KUNKEL, S.L. & N. GODESSART. 2002. Chemokines in autoimmunity: from pathology to therapeutics. Autoimmunity Rev. 1: 313-320.
33. SZEKANECZ, Z. et al. 2003. Chemokines and chemokine receptors in rheumatoid arthritis. Semen. Immunol. 15: 15-21.
34. HORUK, R. 2003. Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 29: 369-375.
35. MATTHYS, P. et al. 2001. AMD3100, a potent and specific antagonist of the stromal cell-derived factor chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J. Immunol. 167: 4686-4692.
36. NAYA, A. et al. 2001. Design, synthesis, and discovery of a novel CCR1 antagonist. J. Med. Chem. 44: 1429-1435
37. GARCIA-RAMALLO, E. et al. 2002. Resident cell chemokine expression serves as the major mechanism for leukocyte recruitment during local inflammation. J. Immunol. 169: 6467-6473.
38. YANG, Y.F. et al. 2002. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur. J. Immunol. 32: 2124-2132.
39. GONG, J.H. et al. 2004. Post-onset inhibition of murine arthritis using combined chemokine antagonist therapy. Rheumatology (Oxford) 43: 39-42.
40. PLATER-ZYBERK, C. et al. 1997. Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. Immunol. Lett. 57: 117-220.
41. QUINONES, M.P. et al. 2004. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J. Clin. Invest. 113: 856-866.
42. IZIKSON, L. et al. 2000. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 192: 1075-1080.
43. GAUPP, S. et al. 2003. Experimental autoimmune encephalomyelitis (EAE) in CCR2-/-mice. Am. J. Pathol. 162: 139-150.
44. BHALAY, G. & A. DUNSTAN. 2004. Chemokine receptors and drug discovery-SMR meeting. I. Drugs 7: 441-443.
45. GLADUE, R.P., S.H. ZWILLICH, A.T. CLUCAS & M.F. BROWN. 2004. CCR1 antagonists for the treatment of autoimmune diseases. Curr. Opin. Investig. Drugs 5: 499-504.
46. PROUS SCIENCE PUBLISHERS. 2005. Prous Science Integrity database. Barcelona.
47. ELICES, M.J. 2002. BX-471 Berlex. Curr. Opin. Investig. Drugs 3: 865-869.
48. HARINGMAN, J.J. et al. 2003. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62: 715-721.
49. BERRY, K. et al. 2004. Evaluation of T0906487, a CXCR3 antagonist, in a phase 2a psoriasis trial [Abstract]. Inflammation Res. Suppl. 53: pS222.